二肽基肽酶IV抑制剂与二甲双胍联用的研究进展  

Research progress in application of dipeptidyl peptidase-IV inhibitors combined with metformin

作　　者：黄建权[1] 王观春[1] 

机构地区：[1]航天中心医院药剂科,北京100049

出　　处：《中国新药杂志》2012年第23期2753-2757,共5页Chinese Journal of New Drugs

摘　　要：二肽基肽酶IV(DPP-4)抑制剂联合二甲双胍能有效控制2型糖尿病(T2DM)患者的血糖,同时明显降低HbA1c水平,且耐受性良好,无体重增加等不良反应,低血糖发生率也较低。本文通过查阅文献介绍了DPP-4抑制剂的作用机制、代表药物以及与二甲双胍联用的优势和现状,综述了DPP-4抑制剂与二甲双胍联合应用在T2DM治疗中的进展。Combined with metformin, dipeptidyl peptidase-IV （DPP-4） inhibitors can be used to achieve the purpose of glycemia control and significantly reduce HbAlc levels in patients with type 2 diabetes mellitus （T2DM）. The drug combination has been proved to be well-tolerated with low rates of hypoglycaemia, and have no side effect of weight gain. Based on the recent literature, we introduced the states and advantages of combination of DPP-4 inhibitors with metformin, and the mechanisms of action, and typical drugs of DPP-4 inhibitors; reviewed the research progress in the combination for the treatment of patients with T2DM.

关 键 词：二肽基肽酶IV 二甲双胍 联用 2型糖尿病 

分 类 号：R977.15[医药卫生—药品]